The Merck’s M&A over Cubist benefits Dong-A ST

Published: 2014-12-11 13:00:34

Updated: 2014-12-11 13:17:04

It is analyzed that the Merck’s Merger and Acquisition (M&A)with Cubist will benefit Dong-A ST.

Cubist, a pharmaceutical company specializing in antibiotics, which taken over by Merck, is a company that has acquiredthe Dong-A ST’s super antibiotic ‘Sivextro’.

A component ‘DA-7218’ developed by Dong-A ST has been completed with clinical studies by Cubist, acquired the sale rights from the Food...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.